非奈利酮对慢性肾脏病患病率与死亡率的影响
该研究为预设的FINE-HEART汇总分析,纳入三项试验中18991例参与者,分析14180例。非奈利酮较安慰剂降低心血管死亡或心衰住院风险(HR 0.83,95%CI 0.75-0.93,P=0.001),且降低复合肾脏结局,高UACR者获益更明显(交互P=0.04)。
要点
- 非奈利酮较安慰剂降低心血管死亡或心衰住院风险,HR 0.83(95%CI 0.75-0.93,P=0.001)。
- 复合肾脏结局的获益随基线UACR升高而更明显(交互P=0.04)。
- 非奈利酮组严重不良事件较少(34% vs 36%),但高钾血症相关永久停药较多(2% vs 1%)。
核心结论
- 在这一预设的FINE-HEART分析中,非奈利酮在合并2型糖尿病的慢性肾脏病患者中降低了心血管、肾脏及死亡事件。
研究设计与样本
- 预设的参与者水平汇总分析(FINE-HEART),汇总FIDELIO-DKD、FIGARO-DKD和FINEARTS-HF三项试验中FINEARTS-HF合并2型糖尿病、CKD和白蛋白尿的参与者与FIDELIO-DKD和FIGARO-DKD入组者。
- 汇总试验参与者共18991例,其中14180例纳入分析;平均年龄65±10岁,女性31%,平均eGFR 58±22 ml/min/1.73 m2,中位UACR 478(四分位距167-1103)mg/g。
- 采用Cox比例风险回归模型评估非奈利酮与安慰剂对心血管事件、复合肾脏结局、全因住院和死亡率的影响,按试验和地理区域分层。
主要发现
- 非奈利酮较安慰剂降低心血管死亡或心衰住院(HR 0.83;95%CI 0.75-0.93;P=0.001),基线eGFR(交互P=0.18)、UACR(交互P=0.60)或糖化血红蛋白(交互P=0.51)均未见异质性证据。
- 非奈利酮还似乎降低心血管死亡、心衰住院、主要不良心血管事件、新发心房颤动和复合肾脏结局。
- 复合肾脏结局的获益随基线UACR升高而似乎更明显(交互P=0.04)。
- 敏感性分析中,纳入FINEARTS-HF合并2型糖尿病且至少中等风险CKD的参与者时,非奈利酮似乎一致降低心血管死亡或心衰住院,与UACR无关(交互P=0.22);纳入FINEARTS-HF白蛋白尿性CKD但无糖尿病的参与者时,与糖化血红蛋白无关(交互P=0.59)。
- 非奈利酮组严重不良事件较安慰剂组少见(34% vs 36%),但高钾血症相关永久停药更常见(2% vs 1%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: In three trials, finerenone reduced a range of cardiovascular and kidney outcomes in persons with diabetes and CKD. Benefits of finerenone were observed across a broad spectrum of glycemia and kidney structure and function. In exploratory analyses, cardiovascular benefits of finerenone appeared consistent in CKD populations without diabetes. BACKGROUND: Finerenone has been shown to reduce cardiovascular and kidney events in individuals with CKD and type 2 diabetes. Pooling data from all completed outcomes trials evaluating finerenone to date may enhance understanding of its effects on morbidity and mortality in this high-risk population. METHODS: In this prespecified participant-level pooled analysis of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD), Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD), and Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF) trials (FINE-HEART), FINEARTS-HF participants with type 2 diabetes, CKD, and albuminuria were pooled with persons enrolled in FIDELIO-DKD and FIGARO-DKD. Treatment effects of finerenone versus placebo on cardiovascular events, composite kidney outcomes, all-cause hospitalization, and mortality were evaluated using Cox proportional hazards regression models, stratified by trial and geographic region. RESULTS: Among 18,991 pooled trial participants, 14,180 (mean age, 65±10 years; 31% female; mean eGFR, 58±22 ml/min per 1.73 m2; median urine albumin-to-creatinine ratio (UACR), 478 [interquartile range, 167–1103] mg/g) were included in the analysis. Finerenone reduced cardiovascular death or heart failure hospitalization (hazard ratio, 0.83; 95% confidence interval, 0.75 to 0.93; P = 0.001) compared with placebo, without evidence of heterogeneity according to baseline eGFR (Pinteraction = 0.18), UACR (Pinteraction = 0.60), or glycated hemoglobin (Pinteraction = 0.51). Finerenone additionally appeared to reduce cardiovascular death, heart failure hospitalization, major adverse cardiovascular events, new-onset atrial fibrillation, and the composite kidney outcome. Benefits on the composite kidney outcome appeared greater with higher baseline UACR (Pinteraction = 0.04). In sensitivity analyses evaluating a broader range of participants with CKD, finerenone appeared to consistently reduce cardiovascular death or heart failure hospitalization irrespective of (1) UACR (Pinteraction = 0.22) when FINEARTS-HF participants with type 2 diabetes and at least moderate-risk CKD were included and (2) glycated hemoglobin (Pinteraction = 0.59) when FINEARTS-HF participants with albuminuric CKD but without diabetes were included. Serious adverse events were less common with finerenone versus placebo (34% versus 36%), but hyperkalemia-related permanent treatment discontinuations were more common (2% versus 1%). CONCLUSIONS: In this prespecified FINE-HEART analysis, finerenone reduced cardiovascular, kidney, and mortality events across a wide spectrum of CKD in persons with type 2 diabetes. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: PROSPERO, CRD42024570467
引用
- Ostrominski JW, Filippatos G, Claggett BL, et al. Effect of Finerenone on Morbidity and Mortality in CKD. J Am Soc Nephrol. 2025. PMID: 40938666. doi:10.1681/ASN.0000000823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。